About CureMarkMediSciences
CureMarkMediSciences is a Healthcare company based in India founded in 2020. It develops and distributes quality pharmaceutical products for various medical needs worldwide. It operates on a B2B and Distribution model. Its Indian entity Curemark Medi Sciences Private Limited reported revenue of ₹1.65 Cr. CureMarkMediSciences offers products and services including Antipyretics & Anti-Inflammatory, Anti-Biotic & Antibacterial, Antacid & Anti-Ulcerant, Multivitamin & Hematinics, and Cardiac & Diabetic. Its focus areas include Pharmaceuticals, Distribution, Franchise Network and Medicine Manufacturing. Its competitors include Inventia Healthcare, Zim Labs and Halewood Laboratories; 2 of its 3 listed competitors have raised funding.
Company details
Cure Mark Medisciences Pvt. Ltd. is a pharmaceutical company based in Bengaluru, India, that focuses on creating and distributing a wide range of medicines, including antipyretics, antibiotics, and cardiac drugs. They prioritize innovation, quality, and affordability, serving patients through franchises and hospitals across India and internationally. The company employs a dedicated team of professionals to ensure efficient distribution and meet customer needs effectively.
- Headquarters India
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website curemarkmedisciences.com
- Social Facebook Instagram
- Legal Name Cure Mark Medisciences Pvt. Ltd.
- Date of Incorporation 12 Mar, 2018
- Jurisdiction Hubli, Karnataka, India
- Annual Revenue₹1.65 Cr
FY 2025 · -10% YoY
- Net Loss-₹2.9 Lakh
FY 2025 · -2% margin
- EBITDA₹7.6 Lakh
FY 2025 · 5% margin
Associated legal entities of CureMarkMediSciences
CureMarkMediSciences operates through Curemark Medi Sciences Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Curemark Medi Sciences Private Limited CIN U74999KA2018PTC111014 | Active | 12 Mar 2018 | Hubli, Karnataka | ₹1.7 Cr | 4 | View details |
Products & Services of CureMarkMediSciences
CureMarkMediSciences offers a comprehensive portfolio of products and services, including Antipyretics & Anti-Inflammatory, Anti-Biotic & Antibacterial, Antacid & Anti-Ulcerant, Multivitamin & Hematinics, and Cardiac & Diabetic.
Products for reducing fever and treating inflammation effectively.
Drugs to fight bacterial infections and promote health.
Treats acidity and ulcers for digestive health relief.
Nutritional products to support overall body health and vitality.
Medicines for managing heart conditions and diabetes control.
Board of directors of Curemark Medi Sciences Private Limited (CureMarkMediSciences)
Curemark Medi Sciences Private Limited is the primary company behind CureMarkMediSciences. The board of Curemark Medi Sciences Private Limited currently have 4 directors; the longest-serving is Umesh Naganagoud Hotagigoudr, appointed in 2018.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Umesh Naganagoud Hotagigoudr DIN 08083649 | Managing Director | 12 Mar 2018 | 8 yrs 7 mo | Curemark Medi Sciences Private Limited |
| Pallavi Umesh Hotagigouder DIN 08083650 | Director | 12 Mar 2018 | 8 yrs 7 mo | Curemark Medi Sciences Private Limited |
| Sukesha Manjupoojari DIN 08083651 | Director | 12 Mar 2018 | 8 yrs 7 mo | Curemark Medi Sciences Private Limited |
| Pradeep Hodaghatta Puttaraju DIN 06712653 | Director | 01 Oct 2020 | 6 yrs | Curemark Medi Sciences Private Limited |
Financials of CureMarkMediSciences
Figures of Curemark Medi Sciences Private Limited, the primary company behind CureMarkMediSciences, for FY 2025. Revenue was ₹1.65 Cr (-10% year on year). Net loss was -₹2.9 Lakh (-2% margin). EBITDA was ₹7.6 Lakh (5% margin). Revenue has grown at a compounded annual rate of -2% over three years and +13% over five years.
- ₹1.65 CrRevenue · FY 2025 · -10% YoY
- -₹2.9 LakhNet loss · -2% margin
- ₹7.6 LakhEBITDA · 5% margin
- ₹1 LakhPaid-up capital
- -2%Revenue CAGR, 3 years
- +13%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Curemark Medi Sciences Private Limited are on its company page.
Detailed financial statements for CureMarkMediSciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of CureMarkMediSciences
CureMarkMediSciences has 3 listed competitors in our database, 2 of them funded. They include Inventia Healthcare, Zim Labs and Halewood Laboratories.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inventiahealthcare.com | 1985 | Mumbai, India | $42.49M | 980 | Oral solid drug delivery systems are manufactured and developed. | |
| zimlab.in | 1989 | Nagpur, India | $8.2M | 598 | Solid and semisolid dosage forms are developed and manufactured. | |
| halewoodlabs.com | 1984 | Ahmedabad, India | 348 | Provides contract manufacturing services for food, pharmaceuticals, and related products globally. |
Detailed competitors of CureMarkMediSciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CureMarkMediSciences
CureMarkMediSciences was founded in 2020.
CureMarkMediSciences is headquartered in India.
The primary company behind CureMarkMediSciences, Curemark Medi Sciences Private Limited, reported revenue of ₹1.65 Cr for FY 2025, down 10% year on year.
Cure Mark Medisciences Pvt. Ltd. is a pharmaceutical company based in Bengaluru, India, that focuses on creating and distributing a wide range of medicines, including antipyretics, antibiotics, and cardiac drugs. They prioritize innovation, quality, and affordability, serving patients through franchises and hospitals across India and internationally. The company employs a dedicated team of professionals to ensure efficient distribution and meet customer needs effectively.
CureMarkMediSciences's top competitors include Inventia Healthcare, Zim Labs and Halewood Laboratories.
CureMarkMediSciences offers Antipyretics & Anti-Inflammatory, Anti-Biotic & Antibacterial, Antacid & Anti-Ulcerant, Multivitamin & Hematinics, and Cardiac & Diabetic.
CureMarkMediSciences operates through Curemark Medi Sciences Private Limited.
The legal entities of CureMarkMediSciences currently have 4 directors, including Pradeep Hodaghatta Puttaraju, Umesh Naganagoud Hotagigoudr, Pallavi Umesh Hotagigouder and others.